Hey {{first_name|default:there}}, it’s Vadim 👋
If you’re building a biotech company, you’ve probably seen the headlines about China’s increasing relevance across the industry.
But what does that actually change for what you’re building? How does it impact where you develop your program, how you differentiate it, and who might fund it?
That’s what I wanted to unpack with Marc Appel, founder and managing partner of Pacific Bridge NY, in this week’s podcast.
Through his work at Pacific Bridge NY, Marc helps bring Asian biotech innovation into U.S. development and company building, while connecting Western founders with partners and capabilities across Asia - giving him a firsthand view of where founders face stronger competition, where collaboration can help, and what investors need to see to back an idea.
In preparing for our conversation, I went pretty deep in my research on China and the wider Asia-Pacific biotech ecosystem.
Instead of putting all that work into the Bio Founder GPS Archives after we filmed the episode, I decided to compile it into a printable industry report: Biotech’s Shifting Center of Gravity.
You can grab it for free in the bonus resources section at the end of this newsletter.
Here’s what we covered with Marc:
What’s driving China’s biotech rise and “China speed”
How to differentiate your science and build a defensible competitive advantage
Why founders need to think globally when designing clinical trials
Opportunities across China and the wider Asia-Pacific ecosystem
How licensing and partnerships can help advance or reposition your company
How family offices approach biotech investing, and what makes a credible fundraising pitch
You can watch the full interview, or listen via your podcast platform of choice below.
Listen + subscribe: Spotify / Apple Podcasts / YouTube